Prelude Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update
Enrollment of Phase 1 study of PRT13722, a first-in-class highly-selective oral KAT6A degrader in HR+ breast cancer is underway; initial proof of concept data anticipated in the 2 nd half of 2027